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Today, irinotecan in combination with bolus and/or infusional 5-FU/FA constitutes a standard ﬁrst-line treatment for patients
with metastatic colorectal cancer. In an attempt to further improve clinical outcome, the use of irinotecan in combination with
novel, targeted agents has been investigated. The theoretical attraction of combining irinotecan with targeted therapies is that this
can improve the eﬃcacy of treatment, but, due to the mainly non-overlapping toxicities of the agents involved, the toxicity of
treatment should not be exacerbated. In this article we discuss recent data from clinical studies looking at the combinations of
irinotecan with the 5-ﬂuorouracil (5-FU) pro-drug, capecitabine, the cyclo-oxygenase (COX-2) inhibitor, celecoxib, and monoclonal
antibodies against the epidermal growth factor receptor (cetuximab) and vascular endothelial growth factor (bevacizumab).
 2004 Elsevier Ltd. All rights reserved.
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Results from two pivotal phase III clinical trials have
demonstrated that the addition of irinotecan to infu-
sional or bolus 5-ﬂuorouracil (5-FU)/folinic acid (FA)
regimens signiﬁcantly improves response rate, time to
disease progression and median survival time [1,2].
More recently, irinotecan in combination with the high-
dose infusional AIO 5-FU/FA regimen has also yielded
encouraging results [3]. Irinotecan in combination with
bolus or infusional 5-FU/FA constitutes a standard
ﬁrst-line therapy for patients with metastatic colorectal
cancer. The activity of irinotecan in colorectal cancer
has prompted its investigation in combination with* Corresponding author. Tel.: +49-40-2546-2501; fax: +49-40-2546-
2500.
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doi:10.1016/j.ejcsup.2004.04.010agents other than 5-FU/FA [4]. The key to improving
clinical outcome is to enhance eﬃcacy without increas-
ing the toxicity of treatment. Thus, much attention has
been focused on combining irinotecan with speciﬁc,
targeted agents that have no, or only partially overlap-
ping, toxicities. In this article, we review the recent data
for irinotecan in combination with capecitabine, the
cyclo-oxygenase inhibitor, celecoxib, and the monoclo-
nal antibodies bevacizumab and cetuximab, in the
treatment of advanced and metastatic colorectal cancer.2. Irinotecan plus capecitabine
Capecitabine is an orally active, ﬂuoropyrimidine
pro-drug which is converted enzymatically to 5-FU
within tumour cells. Thus, capecitabine has the advan-
tage not only of convenience of administration, which is
attractive to patients, but also of being tumour-selective.
Pooled data from two large, randomised, phase III trials
Fig. 1. (a) Progression-free and (b) overall survival in patients with
locally advanced or metastatic colorectal cancer receiving a combina-
tion of capecitabine and irinotecan, administered either weekly or
three-weekly.
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(1250 mg/m2 twice daily for 14 days every three weeks)
with the Mayo Clinic 5-FU/FA regimen (5-FU 425 mg/
m2 plus FA 20 mg/m2 days 1–5, every four weeks) as
ﬁrst-line treatment for metastatic colorectal cancer
showed that capecitabine was associated with a signiﬁ-
cantly higher response rate (26% vs. 17%, P < 0:0002)
and a similar time to disease progression, overall sur-
vival and duration of response compared with bolus 5-
FU/FA [5]. Moreover, capecitabine demonstrated sig-
niﬁcantly less toxicity than bolus 5-FU/FA in terms of
diarrhoea, stomatitis, nausea, alopecia and neutropenic
fever/sepsis.
The combination of irinotecan and capecitabine has
been investigated as ﬁrst-line therapy in locally ad-
vanced and metastatic colorectal cancer. In a phase I
study in 37 patients with metastatic disease, weekly ad-
ministration of irinotecan (70 mg/m2 for six weeks) in
combination with capecitabine (2000 mg/m2/day in a
split dose for two weeks, starting on days 1 and 22) was
found to be active, with a response rate of 38% [6].
Toxicity was manageable, with diarrhoea being the main
side eﬀect at this dose. Munoz and colleagues reported
the results of a study in which three-weekly adminis-
tration of irinotecan (225 mg/m2 (180 mg/m2 if patients
were over the age of 65 years)) in combination with
capecitabine (2000 [1500] mg/m2/day for two weeks,
from days 2 to 15) was investigated in 56 patients with
locally advanced or metastatic disease [7]. A median of
three cycles of treatment were delivered, with a median
relative dose intensity of 97% for both drugs. Treatment
was well tolerated, even in older patients (P65 years),
with the main toxicity being neutropenia/leukopenia.
However, grade 3/4 diarrhoea and asthenia were re-
ported in 7% and 4% of older patients, respectively, but
in none of the younger patients, suggesting that dose
reduction in such patients may be a consideration. Fe-
brile neutropenia was seen in two patients (one cycle
each) and there were two treatment-related deaths. The
overall response rate among 42 evaluable patients was
45%, with two complete responses and 17 partial re-
sponses [7]. By October 2003, there were 67 evaluable
patients, with a response rate of 46%, a tumour growth
control rate of 81% and a time to progression of 7.4
months.
Borner and colleagues [8] compared the administra-
tion of irinotecan on a weekly (70 mg/m2, days 1, 8, 15,
22 and 29) or a three-weekly (300/240 mg/m2, days 1 and
22) basis in combination with capecitabine (2000 mg/m2/
day, days 1–14, 22–35, every 42 days) in a randomised
phase II trial in metastatic colorectal cancer. A total of
75 patients entered the trial. Compared with three-
weekly administration, weekly administration of irino-
tecan was associated with more grade 3/4 diarrhoea
(32% vs. 19%), but less grade 3/4 neutropenia (5% vs.
19%) and less grade 2/3 alopecia (21% vs. 65%). Pre-liminary response rates were similar for both weekly and
three-weekly irinotecan administration (42% and 41%).
Time to progression was longer with the three-weekly
(9.9 months) compared with weekly (7.2 months) ad-
ministration. By October 2003, updated response data
were markedly higher in the three-weekly administration
group (35% vs. 18%), time to progression was essentially
the same at 9.2 and 6.9 months (Fig. 1(a)) and the
median overall survival was 24.7 months with the
three-weekly regimen and 17.4 months with the weekly
regimen (Fig. 1(b)).
Thus it appears that the combination of irinotecan
and capecitabine is an active and well tolerated combi-
nation. Based on clinical ﬁndings showing a superiority
of the three-weekly irinotecan regimen over the weekly
regimen, the combination of three-weekly irinotecan
with capecitabine is being investigated in further studies.
One such study is European Organization for Research
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mised phase III trial, in which irinotecan in combination
with capecitabine (with or without celecoxib) is being
compared with irinotecan in combination with 5-FU/FA
(with or without celecoxib). This trial is described in
further detail in the next section.3. Irinotecan plus celecoxib
The cyclo-oxygenase (COX) enzyme, which converts
arachidonic acid to prostaglandins, is expressed in two
isoforms: COX-1, which is constitutively expressed, and
COX-2, which is inducible in inﬂammation. A number
of tumours express the COX-2 isoform, including breast
[9,10], head and neck [11], cervical [12] and colorectal
cancer [13–16], and COX-2 overexpression is generally
an indicator of poor prognosis. In colorectal cancer,
COX-2 may be involved in tumour progression via the
modulation of angiogenesis and the proliferation of tu-
mour cells, and interactions with other tumour pro-
moting systems, such as vascular endothelial growth
factor (VEGF) and the epidermal growth factor recep-
tor (EGFR) have been suggested [15,16].
The non-steroidal anti-inﬂammatory drug, celecoxib,
is a selective COX-2 inhibitor. Celecoxib has been
shown to reduce the number of polyps in patients with
familial adenomatous polyposis [17]. Preclinical studies
have shown celecoxib to inhibit cell proliferation and to
induce apoptosis in head and neck cancer cell lines [18].
In addition, celecoxib enhanced the cytotoxicity of a
number of cytotoxic chemotherapeutic drugs, including
5-FU, doxorubicin, vincristine and bleomycin. Others,
using murine models of colorectal cancer, have shown
celecoxib to enhance the antitumour eﬃcacy of irino-
tecan and reduce the severity of late onset diarrhoea in a
dose-dependent manner [19].
The eﬀects of combining celecoxib with irinotecan/
5-FU/FA as ﬁrst-line therapy in advanced colorectal
cancer have recently been reported in two phase II trials,
both of which administered chemotherapy as follows:
irinotecan (125 mg/m2), 5-FU (500 mg/m2) and FA (20
mg/m2) (IFL) weekly for four weeks, followed by a two-
week rest; celecoxib (400 mg bid) was continued
throughout the administration of IFL. Using this regi-
men, Blanke et al. reported a response rate of 28%,
among 18 evaluable patients, with a further 56% of
patients having stable disease [20]. The main grade 3/4
toxicity was neutropenia, which was reported in over
two-thirds (39%) of 23 patients, two of whom also had
fever. Non-haematological toxicity comprised mainly
gastrointestinal eﬀects, including grade 3/4 diarrhoea
(22%) and grade 3/4 nausea (22%). Three patients ex-
perienced cardiovascular toxicity and there was one
toxic death from a stroke, which was thought to be
possibly related to treatment. In the second study, aHoosier Oncology Group Study, patients also received
oral glutamine (10 g tid) in addition to the IFL/celecoxib
regimen described above [21,22]. At a median follow-up
of 7.8 months in 31 evaluable patients, the response rate
was 42%, with two complete and 11 partial responses.
The one-year survival rate was 57%. There were no ep-
isodes of grade 4 diarrhoea reported, although 42% of
patients had grade 3 diarrhoea. Thirty-four percent of
patients had grade 3/4 neutropenia, but there were no
reports of neutropenic fever. There were two treatment-
related deaths (gastrointestinal bleeding/aspiration and
a possible pulmonary embolism).
The beneﬁts of adding celecoxib to irinotecan-based
chemotherapy in metastatic colorectal cancer are now
being investigated in a large multicentre, randomised
phase III trial (EORTC 40015). Patients will receive ei-
ther capecitabine (1000 mg/m2 bid, days 1–14) plus iri-
notecan (250 mg/m2, day 1) every 21 days, or biweekly
infusional 5-FU/FA plus irinotecan (180 mg/m2, day 1)
every 14 days. Irinotecan is administered prior to
capecitabine. In a two-by-two factorial design, patients
will also be randomised to either placebo or celecoxib
(400 mg bid). Seventy-nine centres are involved in this
trial which has a target accrual of 692 patients. Re-
cruitment began in May 2003 and is expected to con-
tinue until the end of 2007.4. Irinotecan plus monoclonal antibodies
4.1. Irinotecan plus cetuximab
The EGFR is a cell membrane growth factor receptor
which plays an important role in cell growth, diﬀeren-
tiation and survival [23–25] and which is now thought to
be central to the growth regulation of various tumours.
The binding of activating ligands, such as epidermal
growth factor (EGF) and transforming growth factor
alpha (TGF-a), to the EGFR is followed by activation
of intracellular tyrosine kinase domains. This leads to a
variety of eﬀects, such as the promotion of angiogenesis
and the inhibition of apoptosis, which can lead to the
development and progression of tumours. Many human
tumours express high levels of EGFR, including CRC
[26–28], in which it is an indicator of reduced survival
[29]. Studies in metastatic colorectal cancer have shown
levels of EGFR expression of 72% and 82% [28,30].
Cetuximab is a chimeric monoclonal antibody that
targets the EGFR and competitively inhibits the binding
of the natural ligands. This inhibits the activation of the
signal transduction pathways that depend on tyrosine
kinase activity. Cetuximab appears to potentiate the
cytotoxic activity of irinotecan. In preclinical studies
using established colorectal tumour xenografts, the ad-
dition of cetuximab to irinotecan improved the inhibi-
tion of tumour growth or tumour regression [31].
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irinotecan-refractory xenografts was also noted, whereas
either agent alone did not control tumour growth. De-
spite the enhancement of irinotecan activity, clinical
study has shown no pharmacokinetic interaction be-
tween irinotecan and cetuximab [32]. A number of
clinical studies have now been conducted investigating
the use of irinotecan in combination with cetuximab in
EGFR-expressing advanced colorectal cancer (Table 1).
Initial studies investigated the use of cetuximab as
second-line therapy in patients with EGFR-expressing
disease refractory to both 5-FU and irinotecan. In an
early study by Saltz et al. [30], the combination of iri-
notecan (at the same dose and schedule that patients had
progressed on) with cetuximab (400 mg/m2 loading dose
followed by 250 mg/m2 weekly) led to a response rate of
17% in 21 patients. In a subsequent study by the same
group, the use of cetuximab alone (at the same dose as
described above) in irinotecan-refractory disease was
associated with a response rate of 11% [33]. The main
toxicity associated with cetuximab is an acne-like skin
rash, which was seen in 61% of patients in the early
study and in 86% in the subsequent study. This rash
does not appear to compromise continued treatment.
Following on from these two non-randomised stud-
ies, a phase II randomised study comparing cetuximab
alone or in combination with irinotecan in patients with
irinotecan-refractory EGFR-expressing metastatic co-
lorectal cancer was carried out [28]. Patients were
randomised to receive cetuximab (400 mg/m2 loading
dose followed by 250 mg/m2 weekly) either alone
(n ¼ 111) or in combination with irinotecan (at the same
dose and schedule on which patients had progressed)
(n ¼ 218). Many patients were heavily pretreated, nearly
half (45%) having received three or more previous linesTable 1
Irinotecan, alone or together with bolus and/or infusional 5-FU/FA, combine
untreated EGFR-expressing metastatic colorectal cancer
Line of therapy Study type Treatmen
Second- or subsequent-line for
irinotecan-refractory disease
Non-randomised [30] Cetuxima
and sched
Non-randomised [33] Single-age
Randomised [28] Cetuxima
and sched
Single-age
First-line Non-randomised [34] Cetuxima
infusiona
First-line Non-randomised [36] Cetuxima
First-line Non-randomised [35] Cetuxima
infusiona
High-dos
Low-dose
See text for details of doses. yPreliminary data. N , number of patients; Pof therapy. The combination of irinotecan and cetux-
imab gave a higher response rate (23% vs. 11%,
P ¼ 0:0074), better tumour growth control (56% vs.
32%, P ¼ 0:0001) and a longer time to disease progres-
sion (4.1 months vs. 1.5 months, P < 0:0001) than ce-
tuximab alone. The results are particularly encouraging
in view of the relatively large number of patients who
had received three or more previous lines of therapy.
There was no correlation between the degree of EGFR
expression and the response to therapy. However, there
was some evidence of a link between the development of
skin toxicity and eﬃcacy: patients receiving the irino-
tecan/cetuximab combination who had any skin reaction
had a better response rate (26% vs. 6%) and a longer
survival (median 9.1 vs. 3 months) than those with no
skin reaction [28].
Three phase II studies have now shown promising
activity of the combination of cetuximab, irinotecan and
diﬀerent regimens of bolus and/or infusional 5-FU/FA
as ﬁrst-line therapy for EGFR-expressing metastatic
colorectal cancer [34–36]. In a study reported by Van
Laethem et al. [35] weekly cetuximab (400 mg/m2
loading dose followed by 250 mg/m2 weekly) was com-
bined with bi-weekly irinotecan (180 mg/m2), FA (400
mg/m2) and bolus 5-FU followed by an infusion of ei-
ther high-dose (2400 mg/m2 46-h infusion) or low-dose
(2000 mg/m2, 46-h infusion) 5-FU. Over the two groups,
12 of 18 patients (67%) had a partial response, and 22%
had stable disease [35]. By October 2003, updated in-
formation showed that out of 22 patients, the response
rate was 59%, with a further 36% of patients with stable
disease, giving a tumour growth control rate of 95%. In
addition, following chemotherapy seven patients were
able to undergo R0 resection for hepatic or lung me-
tastases. There was no diﬀerence in the response rated with cetuximab in the treatment of patients with previously treated or
t N Response rate
PR (%) TGC (%)
b+ irinotecan at the same dose
ule that disease progressed on
121 17 48
nt cetuximab 57 11 33
b+ irinotecan at the same dose
ule that disease progressed on vs.
218 23 56
nt cetuximab 111 11 32
b+ irinotecan/bolus and
l 5-FU/FAy
13 38 46
b+ irinotecan/bolus 5-FU/FA 25 44 64
b+ irinotecan/bolus and
l 5-FU/FA
22 59 95
e 5-FU group vs. 12 58 100
5-FU group 10 60 90
R, partial response; TGC, tumour growth control.
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Fig. 2. Median response duration, progression-free and overall survival
of patients with metastatic colorectal cancer receiving irinotecan/bolus
5-FU/FA in combination with bevacizumab. Results from a rando-
mised phase III trial [41]. IFL, irinotecan, 5-ﬂuorouracil, folinic acid.
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tumour growth control rate was higher in the high-dose
5-FU group (100% vs. 90%). In the high-dose 5-FU
group, diarrhoea was markedly higher than in the low-
dose group (28% vs. 0%) and there were three dose-
limiting toxicities compared with none in the low-dose
group.
The results from these studies show that the combi-
nation of irinotecan and cetuximab is well tolerated and
demonstrates signiﬁcant clinical activity in patients with
heavily pre-treated advanced colorectal cancer. Signiﬁ-
cantly, this combination was highly active in patients
whose disease had progressed on irinotecan as the last
treatment prior to randomisation, indicating that this
combination is able to re-establish the irinotecan-
sensitivity of the disease. Whether or not this is an
agent-speciﬁc ﬁnding remains to be clariﬁed. In addi-
tion, irinotecan/5-FU/FA plus cetuximab is well toler-
ated and very active as ﬁrst-line therapy and further
clinical trials are expected to establish the role of this
combination in the ﬁrst-line setting. Randomised phase
III studies are required to assess the impact on survival
of adding cetuximab to chemotherapy.
4.2. Irinotecan plus bevacizumab
Tumour angiogenesis is necessary for tumour growth,
progression and metastasis. VEGF, which promotes
angiogenesis by binding to receptors on the vascular
endothelium, is a critical growth factor for tumour an-
giogenesis. In a review of 35 studies between 1996 and
2001, VEGF levels were reported to be high in a number
of tumour types, including colorectal cancer [37]. High
levels of VEGF expression are associated with a signif-
icantly poorer overall survival than low levels [38].
Bevacizumab is a recombinant humanised monoclo-
nal antibody directed against VEGF. A recent rando-
mised phase II trial in metastatic colorectal cancer
showed that the addition of bevacizumab (5 mg/kg every
two weeks) to bolus 5-FU/FA led to a higher response
rate (40% vs. 17%), a longer median time to disease
progression (9.0 vs. 5.2 months), and a longer median
overall survival (21.5 vs. 13.8 months) [39]. Thrombosis
was the most signiﬁcant adverse event and was respon-
sible for one patient death. Other toxicities of concern
were proteinuria and epistaxis.
The beneﬁt of adding bevacizumab to ﬁrst-line iri-
notecan-based chemotherapy for advanced disease was
recently shown in a phase II trial [40] and a large
randomised phase III trial [41]. In the phase III trial,
patients were randomised to receive either IFL (irino-
tecan 125 mg/m2, bolus 5-FU 500 mg/m2, FA 20 mg/m2)
plus placebo or IFL plus bevacizumab (5 mg/kg every
two weeks). These formed the primary comparison
groups. A further group of patients received 5-FU (500
mg/m2)/FA (500 mg/m2) plus bevacizumab. At the timeof disease progression, patients were unblinded and able
to continue bevacizumab in combination with second-
line therapy. In the primary comparison groups, the
addition of bevacizumab to IFL (n ¼ 403) resulted in a
signiﬁcantly improved response rate (45% vs. 35%,
P ¼ 0:0029) and an increase in the duration of response
of almost 50% (10.4 vs. 7.1 months, P ¼ 0:0014) (Fig. 2).
In addition, IFL plus bevacizumab was associated with
a longer progression-free survival (10.6 vs. 6.24 months,
P < 0:00001) and a 30% increase in the median survival
(20.3 vs. 15.6 months, P ¼ 0:00003) compared with IFL/
placebo (n ¼ 412). In terms of toxicity proﬁle, in the
phase II study, there were nine thrombotic events, eight
of which were grade 3/4 [40]. In the phase III study, only
hypertension was found to be signiﬁcantly increased in
patients receiving bevacizumab (22.4% vs. 8.3%,
P < 0:01) [41]. This was easily managed with oral
medication. There was also some evidence that gastro-
intestinal perforations, although rare, could be increased
by the addition of bevacizumab to IFL (1.5% vs. 0.0%)
[41]. The results from the phase III study are remarkable
because of the large number of patients involved in the
study (which underline the reliability of the data) and
the 30% increase in median overall survival, which is
particularly impressive in this patient group. In addi-
tion, the combination of bevacizumab and IFL has only
a limited cost in terms of toxicity. Combinations of
bevacizumab with infusional 5-FU/FA and either iri-
notecan or oxaliplatin are currently under investigation.
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The combination of irinotecan with bolus and/or in-
fusional 5-FU/FA constitutes a standard ﬁrst-line
treatment for metastatic colorectal cancer. However, the
aim is to further improve patient outcome and to reduce
treatment-related side eﬀects. The results of studies
discussed here show that combining irinotecan with
targeted therapies can improve outcome in terms that
matter to patients, which is by prolonging survival
without increasing the side eﬀects associated with
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